Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
The FDA issued a safety communication regarding Accolade pacemaker devices manufactured by Boston Scientific due to a potential requirement for early device replacement.
This affects Boston Scientific, healthcare providers managing patients with Accolade pacemakers, and regulatory/quality professionals responsible for cardiac rhythm management device compliance.
The potential for early device replacement suggests a possible deviation from expected battery longevity or hardware performance. For regulatory professionals, this indicates a need for heightened vigilance in post-market clinical follow-up and may lead to increased scrutiny of manufacturing or component specifications.
Regulatory and clinical teams should review the specific FDA recommendations regarding patient monitoring and early replacement criteria. Quality units should ensure post-market surveillance systems are capturing related battery or longevity data for these specific models.
Read the FDA’s recommendations related to Accolade pacemaker devices by Boston Scientific and a potential need for early device replacement.
Open in openFDA / FDA.gov